US Earnings Financial Results SEC Filings — August 12, 2026

12-08-2026

SideChannel, Inc. reported a net loss of $974,000 for the nine months ended June 30, 2026, nearly doubling from a $510,000 loss in the prior-year period. Total revenue declined 7.7% to $5.147 million from $5.578 million, driven by a 22.1% drop in vCISO Services revenue to $2.491 million, partially offset by an 11.6% increase in Cybersecurity Software and Services revenue to $2.656 million. Cash used in operations surged to $839,000 from $46,000, and cash and equivalents fell sharply to $326,000 from $1.149 million a year earlier.

• · Depreciation and amortization fell sharply to $12,000 from $148,000 YoY.
• · Stock-based compensation and payments for services decreased to $207,000 from $243,000.
• · Accounts receivable improved by $64,000 (source of cash) vs. a $27,000 use in the prior period.
• · Deferred revenue swung to a $138,000 decrease from a $367,000 increase, indicating lower billings or contract renewals.
• · Cash equivalents consisted entirely of money market funds ($101,000) at June 30, 2026, compared to none a year earlier.
• · Short-term investments (time deposits) were fully liquidated by June 30, 2026, down from $100,000 at September 30, 2025.
• · Outstanding warrants totaled 601,000 with exercise prices ranging from $9.36 to $52.00 and expiration dates through 2031.

12-08-2026

ENERGY RESOURCES 12, L.P. reported a net loss of $924,036 for the six months ended June 30, 2026, a significant improvement from a net loss of $3,435,946 in the prior-year period. Total revenue decreased 7.4% to $13,224,797, driven by lower oil and NGL revenue, though natural gas revenue increased. The partnership swung to a net income of $457,056 in Q2 2026 from a net loss of $2,345,352 in Q2 2025, aided by a $406,472 gain on derivatives and lower depreciation charges.

• · The partnership had a derivative asset of $485,212 as of June 30, 2026, compared to zero at December 31, 2025, and recognized a $406,472 gain on derivatives in Q2 2026.
• · Cash from operations declined 30.7% to $3,880,838 for the six-month period, while capital expenditures more than tripled to $3,745,190.
• · The revolving credit facility was reclassified from non-current ($5.8M at Dec 31, 2025) to current liability ($5.8M at June 30, 2026).
• · No distributions were paid to limited partners in the first half of 2026, compared to $7,072,146 paid in the first half of 2025.
• · Depreciation, depletion, amortization and accretion decreased 33.2% to $5,425,575 for the six-month period.

12-08-2026

Utah Medical Products (UTMD) reported a decline in financial performance for Q2 and H1 2026. Net sales for Q2 2026 fell 14.3% YoY to $8.529M, and net income decreased 11.9% to $2.686M. While the company maintains a strong balance sheet with $87.528M in cash and investments and no debt, the top-line and bottom-line declines reflect ongoing operational headwinds.

• · Gross profit margin remained relatively stable at 55.8% in Q2 2026 vs 56.2% in Q2 2025.
• · Operating income margin was 31.1% in Q2 2026 vs 32.1% in Q2 2025.
• · Litigation fees increased to $498K in Q2 2026 from $284K in Q2 2025.
• · Amortization expense decreased sharply to $16K in Q2 2026 from $540K in Q2 2025.
• · Cash provided by operating activities fell to $4.492M in H1 2026 from $7.337M in H1 2025, a decline of 38.8%.
• · The company reduced share buybacks significantly: $0.206M in H1 2026 vs $6.708M in H1 2025.
• · Dividends paid remained consistent at $1.976M in H1 2026 vs $2.018M in H1 2025.
• · Foreign currency translation had a negative impact of $536K in H1 2026 vs a positive $2.546M in H1 2025.
• · Total liabilities decreased to $2.539M as of June 30, 2026 from $3.274M as of December 31, 2025.
• · The company has no long-term debt.

12-08-2026

Summit Healthcare REIT, Inc reported a net loss applicable to common stockholders of $188,000 for Q2 2026, compared to net income of $284,000 in Q2 2025, a decline of $472,000. For the six months ended June 30, 2026, the net loss widened to $1,382,000 from $146,000 in the prior year period. Total operating revenue was essentially flat in Q2 at $3,260,000 versus $3,250,000, but declined 3.3% for the six-month period to $6,301,000 from $6,518,000, driven by lower rental revenues and asset management fees.

• · Total assets declined 2.6% from $69,279,000 at Dec 31, 2025 to $67,433,000 at June 30, 2026.
• · Accumulated deficit increased from $90,499,000 at Dec 31, 2025 to $91,881,000 at June 30, 2026.
• · Operating cash flow was negative $124,000 for the six months ended June 30, 2026, compared to positive $289,000 in the prior year period.
• · No distributions were paid to stockholders in the first half of 2026, versus $1,036,000 in the first half of 2025.
• · Two properties (Sundial Assisted Living and Pennington Gardens) reported zero lease revenue for 2026, indicating they may be non-operating or under different arrangements.
• · Weighted average shares outstanding remained constant at 23,027,978 across all periods.
• · Loans payable decreased slightly from $39,858,000 to $39,254,000, a reduction of $604,000.

12-08-2026

ITG, Inc. reported a net loss of $11.4M for the first half of 2026, a sharp reversal from net income of $13.2M in the same period of 2025, driven by a 42.6% surge in revenue to $738.6M but weighed down by a 44.8% jump in cost of revenue and a 75.8% increase in SG&A expenses. The company's cash position fell to $2.5M from $3.7M at year-end 2025, and total debt rose to $845.0M from $759.8M, while members' equity declined 21.4% to $34.4M. Despite strong top-line growth, the company swung to a loss and saw its cash from operations turn negative.

• · Contract assets surged to $309.8M at June 30, 2026 from $222.1M at December 31, 2025, driven by a $87.3M increase in unbilled revenues.
• · Revolving line of credit balance increased to $112.0M from $30.0M at year-end 2025.
• · Interest expense for the six months nearly tripled to $37.8M from $13.7M in the prior year period.
• · Cash used in operations was $47.0M in H1 2026 vs. cash provided of $11.7M in H1 2025.
• · Depreciation and amortization rose to $41.4M from $27.2M year-over-year.
• · Contingent liabilities decreased to $17.8M from $20.1M at year-end 2025.
• · The company had no cash on its standalone balance sheet (ITG, Inc.) at June 30, 2026.

12-08-2026

First Community Corp (FCCO) reported strong Q2 2026 results with net income of $7.6M ($0.80 diluted EPS), up 46.5% from $5.2M ($0.67) in Q2 2025, driven by higher net interest income and non-interest income. The company completed the acquisition of Signature Bank of Georgia, adding $229.3M in assets and $14.8M in goodwill, which significantly boosted balance sheet totals. However, total non-interest expense rose 16.7% to $15.3M, including $0.5M in merger costs, and the provision for credit losses swung from a release of $237K to a charge of $126K.

• · Net loans held-for-investment grew to $1.56B at June 30, 2026 from $1.30B at December 31, 2025, a 20.2% increase.
• · Allowance for credit losses – loans increased to $18.5M from $13.8M, reflecting loan growth and the acquisition.
• · Intangible assets rose to $2.7M from $289K, and goodwill increased to $29.4M from $14.6M, both due to the Signature Bank acquisition.
• · Cash and cash equivalents at end of period were $162.2M, down from $183.5M a year earlier.
• · Net cash used in operating activities was $4.6M in H1 2026 vs. $6.5M provided in H1 2025.
• · The company paid $2.99M in common dividends in H1 2026, up from $2.30M in H1 2025.
• · Accumulated other comprehensive loss improved slightly to $(18.2M) from $(18.4M) at year-end 2025.

12-08-2026

GEE Group Inc. reported net income of $566K for Q3 FY2026, a significant turnaround from a net loss of $423K in Q3 FY2025, driven by a $196K gain on reduction of promissory notes payable and lower SG&A expenses. However, total net revenues declined 15.3% YoY to $20.8M, with contract staffing services falling 20.1% to $17.0M, partially offset by a 16.3% increase in direct hire placement services to $3.7M. For the nine-month period, the company generated net income of $430K versus a net loss of $34.2M in the prior year, which included a $22.0M goodwill impairment charge.

• · Cash used in operating activities improved to -$805K for 9M FY2026 from -$1,884K in 9M FY2025.
• · The company had no promissory notes payable at June 30, 2026, down from $392K at September 30, 2025.
• · Goodwill remained unchanged at $24,759K; no impairment was recorded in FY2026.
• · Intangible assets, net decreased to $519K from $620K due to amortization.
• · The company acquired intangible assets with a fair value of $1,394K (customer relationships $564K, tradename $68K, non-compete $11K, goodwill $751K) in a prior acquisition.
• · Weighted average diluted shares outstanding increased slightly to 110,160 in Q3 FY2026 from 109,413 in Q3 FY2025.

12-08-2026

Andersen Group Inc. reported revenue of $217.7M for Q2 2026, up 23.7% YoY from $176.0M, and $458.4M for H1 2026, up 19.4% YoY from $384.1M. The company swung to an operating profit of $15.2M in H1 2026 from a $52.5M loss in H1 2025, and net income attributable to the parent was $7.6M versus a $45.4M loss. However, the company's accumulated deficit ballooned to $781.5M from $134.7M at year-end 2025, and cash and cash equivalents fell 29.8% to $175.6M from $250.3M, driven by $83.6M in distributions and $48.9M in debt repayments.

• · Cost of services (excluding D&A) fell 22.9% YoY in Q2 2026 to $173.6M from $225.2M, a key driver of the swing to operating profitability.
• · Sales, general and administrative expenses decreased 6.3% YoY in Q2 2026 to $50.5M from $53.9M, but increased 10.4% YoY in H1 2026 to $98.5M from $89.2M.
• · Interest expense surged to $5.9M in Q2 2026 from $0.1M in Q2 2025, and to $12.1M in H1 2026 from $0.2M in H1 2025.
• · The company issued 822,214 shares of restricted Class A common stock in business combinations during Q2 2026.
• · Redeemable noncontrolling interest was $0 as of June 30, 2026, down from $106.4M at December 31, 2025, while noncontrolling interest was $806.7M, up from $0.
• · Net cash provided by operating activities was $65.8M in H1 2026, up 6.4% from $61.9M in H1 2025.

12-08-2026

Local Bounti Corporation reported Q2 2026 revenue of $13.85M, up 14.4% YoY from $12.1M, and H1 2026 revenue of $27.19M, up 14.7% YoY from $23.71M. However, gross profit declined 28.9% in Q2 to $1.05M (from $1.47M) due to rising cost of goods sold, and the net loss attributable to common stockholders narrowed to $19.82M in Q2 from $21.58M a year ago. The company continues to operate with a negative stockholders' deficit of $196.89M and total liabilities of $599.57M, while cash and cash equivalents decreased to $3.63M from $4.23M at year-end 2025.

• · Total operating expenses decreased 11.4% YoY in Q2 2026 to $14.99M from $16.92M, and 10.7% in H1 2026 to $30.46M from $34.12M.
• · Research and development expenses fell 29.4% YoY in Q2 2026 to $4.58M from $6.49M, and 23.6% in H1 2026 to $10.29M from $13.46M.
• · Sales and marketing expenses increased 20.2% YoY in Q2 2026 to $2.88M from $2.39M, and 13.6% in H1 2026 to $5.12M from $4.51M.
• · General and administrative expenses decreased 6.3% YoY in Q2 2026 to $7.54M from $8.05M, and 6.8% in H1 2026 to $15.05M from $16.15M.
• · Interest expense, net decreased 2.5% YoY in Q2 2026 to $4.49M from $4.60M, and 63.7% in H1 2026 to $8.52M from $23.44M (largely due to lower paid-in-kind interest).
• · Change in fair value of warrant liabilities was a loss of $1.39M in Q2 2026 vs. a loss of $1.50M in Q2 2025; for H1 2026 a gain of $3.86M vs. a loss of $5.01M in H1 2025.
• · Net cash used in operating activities improved 26.4% to $13.44M in H1 2026 from $18.27M in H1 2025.
• · Capital expenditures (purchases of property and equipment) dropped 80.2% to $2.15M in H1 2026 from $10.88M in H1 2025.
• · The company had $10.13M in total cash and restricted cash at June 30, 2026, down from $13.17M a year earlier.
• · Accrued liabilities increased significantly to $6.65M at June 30, 2026 from $3.65M at December 31, 2025.
• · Accounts payable rose to $14.32M from $11.78M over the same period.
• · The company's accumulated deficit grew to $550.15M from $517.61M at year-end 2025.
• · Stock-based compensation decreased 56.0% YoY in Q2 2026 to $1.0M from $2.26M, and 30.2% in H1 2026 to $1.99M from $2.85M.
• · Depreciation and amortization was relatively flat: $5.57M in Q2 2026 vs. $5.86M in Q2 2025, and $11.20M vs. $11.74M in H1 periods.
• · The company issued $14.92M in long-term debt, net of issuance costs, during H1 2026.
• · No preferred stock or common stock was issued for cash in H1 2026 (vs. $21.41M and $3.54M respectively in H1 2025).

12-08-2026

Grocery Outlet Holding Corp. reported mixed results for the 13 and 26 weeks ended July 4, 2026. Net sales grew 1.1% YoY to $1,192,764M in Q2 and 2.3% YoY to $2,359,116M for the first half, with gross profit essentially flat. However, the company recorded a $158,000M goodwill impairment in H1 2026, driving a net loss of $174,696M for the period (vs. a net loss of $18,356M in H1 2025). Q2 net income improved slightly to $5,626M from $4,961M a year ago, but retained earnings turned negative to ($18,179M) from $156,517M at year-end.

• · Restructuring charges were $5,428M in Q2 2026 vs $11,157M in Q2 2025, and $23,619M in H1 2026 vs $45,032M in H1 2025.
• · Goodwill impairment of $158,000M was recorded in H1 2026; none in H1 2025.
• · Cash provided by operating activities fell 27.8% to $95,708M in H1 2026 from $132,563M in H1 2025.
• · Capital expenditures (purchases of property and equipment) were $94,507M in H1 2026, down from $119,669M in H1 2025.
• · The company drew $20,000M from its revolving credit facility in H1 2026 and made no repayments, increasing revolver balance to $240,000M at July 4, 2026 from $220,000M at January 3, 2026.
• · Perishable net sales were $455,372M in Q2 2026 (up 1.0% YoY) and $896,359M in H1 2026 (up 1.7% YoY). Non-perishable net sales were $737,392M in Q2 2026 (up 1.2% YoY) and $1,462,757M in H1 2026 (up 2.8% YoY).

12-08-2026

Nano Nuclear Energy Inc. (NNE) reported its first-ever revenue of $214,042 for the three and nine months ended June 30, 2026, compared to zero revenue in the prior-year periods, driven by the May 2026 acquisition of Secured Transportation Services LLC (STS). However, the company's net loss widened to $10.1M in Q3 FY26 from $7.6M a year ago, and operating expenses surged 68% to $15.9M. Total assets more than doubled to $628.0M from $228.7M at September 30, 2025, primarily due to a $426.8M common stock issuance, while the accumulated deficit grew to $83.3M.

• · The company generated its first-ever revenue of $214,042 in Q3 FY26, all from the STS acquisition, with a gross margin of $62,211.
• · General and administrative expenses rose to $11.9M in Q3 FY26 from $5.3M in Q3 FY25, a 123% increase.
• · Research and development expenses increased to $4.0M in Q3 FY26 from $3.7M in Q3 FY25, a 9% increase.
• · Net cash used in operating activities was $18.7M for the nine months ended June 30, 2026, compared to $14.7M in the prior-year period.
• · Net cash used in investing activities was $297.6M for the nine months ended June 30, 2026, primarily for short-term investments ($281.2M) and the STS acquisition ($5.8M).
• · Net cash provided by financing activities was $411.5M for the nine months ended June 30, 2026, driven by $426.8M in common stock proceeds.
• · The company recorded $7.0M in equity-based compensation for the nine months ended June 30, 2026, down from $17.5M in the prior-year period.
• · Goodwill of $4.2M and intangible assets of $5.5M were recognized as of June 30, 2026, related to the STS acquisition.
• · The company has deferred acquisition consideration of $3.3M (current and non-current) related to the STS acquisition.
• · The company expects to close the sale of its ODIN™ microreactor design to Cambridge Atomworks by November 30, 2026.
• · The KRONOS MMR™ Construction Permit Application was submitted to the NRC on April 2, 2026, and accepted for review on May 18, 2026.
• · The company anticipates launching its fuel supply chain business in late 2026 or early 2027, but has not yet entered into a definitive agreement.

12-08-2026

Octave Intelligence Ltd (OCTV) reported a net loss of $1.97M for Q2 2026 vs. a $75K profit in Q2 2025, driven by a $2.14M impairment charge. Total revenue declined 3.6% YoY to $398K, with subscription revenue growing 5.8% to $283K but license revenue falling 23.3% and services revenue dropping 19.5%. The company completed a distribution from Hexagon, receiving $625K in cash payments and issuing new equity, while total assets fell 23% to $6.69M.

• · Goodwill decreased from $6.22M to $4.55M, a decline of 26.8%.
• · Intangible assets, net decreased from $1.65M to $1.16M, a decline of 29.6%.
• · Long-term debt of $621K was incurred during H1 2026; there was no long-term debt at Dec 31, 2025.
• · Operating cash flow was $241K in H1 2026 vs $249K in H1 2025, a slight decline of 3.1%.
• · Stock-based compensation expense was $6.7M in H1 2026, nearly flat vs $6.8M in H1 2025.
• · The company had a $625K cash payment to Hexagon in connection with the Distribution.
• · Net transfers to Hexagon were $16K in H1 2026 vs $166K in H1 2025.
• · The company issued Class A and Class B ordinary shares during H1 2026, with $110 and $2,574 in par value respectively, and $6.78M in additional paid-in capital.

12-08-2026

West Enclave Merger Corp. (WENC), a SPAC, reported net income of $509,855 for Q2 2026 and $469,457 for H1 2026, driven by interest income from its trust account. The company completed its IPO and private placement, raising gross proceeds of $116.15 million, and held $116.8 million in trust as of June 30, 2026. However, operating expenses exceeded operating income, resulting in a loss from operations of $141,596 for Q2 and $181,994 for H1.

• · Total assets increased from $454,470 at December 31, 2025 to $117,806,772 at June 30, 2026.
• · Total liabilities increased from $52,580 to $430,544 during the same period.
• · Ordinary shares subject to possible redemption: 11,500,000 shares at a redemption value of $10.16 per share as of June 30, 2026.
• · Accretion of ordinary shares to redemption amount was $6,605,334 during Q2 2026.
• · Net cash used in operating activities was $234,681 for H1 2026.
• · Net cash provided by financing activities was $117,264,320 for H1 2026.
• · The company had a promissory note – related party of $2,420 at December 31, 2025, which was repaid during H1 2026.
• · The company received $1,630 from issuance of EBC shares and $1,339 in advances from related party.

12-08-2026

CoreWeave reported revenue of $2,575M for Q2 2026, more than doubling from $1,212M in Q2 2025, and $4,653M for the first half of 2026 versus $2,194M a year earlier. However, the company swung to an operating loss of $49M in Q2 2026 from an operating profit of $19M in Q2 2025, and net loss widened to $626M from $290M. Total assets surged to $77,070M from $49,302M at year-end 2025, driven by massive capital spending, while total debt rose to $35,068M from $21,373M.

• · Customer concentration: Customer A accounted for 36% of Q2 2026 revenue (down from 71% in Q2 2025) and 40% of H1 2026 revenue (down from 72% in H1 2025). Customer B contributed 26% in Q2 2026 and 23% in H1 2026, up from less than 10% in the prior year periods.
• · Interest expense net increased to $640M in Q2 2026 from $267M in Q2 2025, and to $1,176M in H1 2026 from $531M in H1 2025.
• · Depreciation and amortization expense rose to $2,540M in H1 2026 from $1,003M in H1 2025.
• · Stock-based compensation expense was $318M in H1 2026, slightly down from $329M in H1 2025.
• · The company had $6,904M in total cash, cash equivalents, and restricted cash as of June 30, 2026, up from $2,054M a year earlier.
• · Non-cash investing and financing activities included $9,796M in liabilities related to property and equipment additions (including OEM financed additions) in H1 2026, up from $2,155M in H1 2025.
• · Operating lease right-of-use assets acquired through lease liability totaled $8,359M in H1 2026 versus $969M in H1 2025.
• · The company purchased capped calls related to convertible senior notes for $492M in H1 2026.
• · Total stockholders' equity improved to $5,024M as of June 30, 2026 from $3,335M at December 31, 2025, driven by additional paid-in capital from private placements and stock compensation.
• · Net loss per share (basic and diluted) was $(1.14) in Q2 2026 versus $(0.60) in Q2 2025; for H1 2026 it was $(2.53) versus $(1.73) basic and $(1.79) diluted in H1 2025.

12-08-2026

Legend Spices, Inc. filed its annual report for the year ended December 31, 2025, reporting a net loss of $18,787, a significant improvement from the $31,073 net loss in 2024. However, revenue collapsed 90.7% to just $644 from $6,924 in the prior year, and the company ended the year with zero cash, zero current assets, and a working capital deficit of $17,525. The improvement in net loss was driven by a 52.2% reduction in operating expenses, but the business is essentially non-operational with no revenue-generating activity.

• · Gross profit fell to $285 in FY 2025 from $1,954 in FY 2024, a decline of 85.4%.
• · Sales and marketing expenses were reduced to $0 in FY 2025 from $402 in FY 2024.
• · The company recorded a loss on impairment of inventory of $572 and bad debt expense of $2,727 in FY 2025; no such charges were recorded in FY 2024.
• · Total current liabilities decreased to $17,525 as of December 31, 2025 from $71,985 as of December 31, 2024, primarily due to a reduction in due to related parties from $69,717 to $15,725.
• · Stockholders' deficit improved to $17,525 as of December 31, 2025 from $68,047 as of December 31, 2024, driven by the $69,717 related party debt forgiveness.
• · Net cash used in operating activities was $381 in FY 2025, compared to $32,186 in FY 2024.
• · No financing activities occurred in FY 2025, whereas FY 2024 had $32,884 in related party notes payable.

12-08-2026

Nuveen Churchill Private Capital Income Fund reported a mixed quarter for the period ended June 30, 2026. Net investment income grew 28% YoY to $32.7M for Q2 2026, driven by a 46% increase in total investment income. However, the fund recorded significant net unrealized depreciation of $10.6M in Q2 2026 (vs. $1.3M in Q2 2025), leading to a net increase in net assets from operations of only $22.3M, up just 7% from $20.9M in the prior year quarter. The fund completed a major acquisition of BDC V during the period, acquiring $841M in investments and assuming $511M in debt.

• · Total distributable earnings (loss) worsened to -$49.3M as of June 30, 2026 from -$20.9M at Dec 31, 2025.
• · Net realized loss on investments for H1 2026 was $1.8M, improved from a $3.1M loss in H1 2025.
• · Net unrealized depreciation on investments for H1 2026 was $26.4M, more than double the $11.7M in H1 2025.
• · Cash used in operating activities for H1 2026 was $558.1M, compared to $148.0M used in H1 2025, largely due to the BDC V Acquisition.
• · The fund issued $167.2M in new common shares and had $55.8M in share repurchases during H1 2026.
• · Distributions paid during H1 2026 were $37.6M, up from $25.2M in H1 2025.

12-08-2026

Oaktree Strategic Credit Fund reported net investment income of $91.2M for Q3 FY26 (three months ended June 30, 2026), up 10% from $83.0M in the prior-year quarter. However, total net assets declined 5.8% to $4.28B from $4.54B at fiscal year-end, driven by significant net realized and unrealized losses of $139.5M for the nine-month period and $197.7M in share repurchases. Net asset value per share fell 3.3% to $22.32 from $23.09 at September 30, 2025.

• · The fund initiated a control investment during the period, with cost of $13.1M and fair value of $13.1M as of June 30, 2026.
• · Net realized and unrealized losses for the nine months ended June 30, 2026 totaled $139.5M, compared to $19.0M in the prior-year period.
• · Share repurchases were significant: $495.8M for Class I and $203.3M for Class S during the nine months ended June 30, 2026.
• · The fund's leverage increased: credit facilities payable rose 9.1% to $1.47B, while unsecured notes payable decreased slightly to $1.13B.
• · Total portfolio investments represent 158.9% of net assets, indicating significant leverage.
• · Derivative assets at fair value were $18.2M, while derivative liabilities were $4.6M as of June 30, 2026.
• · The fund has a payable for share repurchases of $197.7M as of June 30, 2026, up from $61.0M at September 30, 2025.
• · Net asset value per share declined to $22.32 from $23.09 at September 30, 2025, a decrease of 3.3%.
• · The fund's cash position decreased 16.3% to $218.1M from $260.4M at September 30, 2025.

12-08-2026

Jefferies Credit Partners BDC Inc. reported strong growth in net investment income for Q2 2026, up 75.6% YoY to $20.1M, driven by a 74.9% increase in total investment income. Total assets grew 21.1% to $1.97B, and net assets increased 24.5% to $843.2M. However, the company recorded net unrealized depreciation of $4.5M in Q2 and $7.1M in H1 2026, leading to a decline in NAV per share from $14.43 to $14.30. Distributions exceeded net investment income, resulting in a slight decrease in accumulated earnings.

• · Total assets increased from $1.63B to $1.97B (21.1%) since December 31, 2025.
• · Debt increased from $919.1M to $1.09B (18.7%) since December 31, 2025.
• · Net realized gains on investments were $0.47M in Q2 2026 and $0.67M in H1 2026.
• · Net unrealized depreciation was $4.5M in Q2 2026 and $7.1M in H1 2026.
• · Distributions to shareholders were $20.2M in Q2 2026 and $37.7M in H1 2026.
• · Net cash used in operating activities was $296.9M in H1 2026.
• · Net cash provided by financing activities was $306.3M in H1 2026.
• · Cash and cash equivalents and restricted cash increased from $40.1M to $49.5M.
• · Class S shares were introduced during H1 2026 with 6,236 shares outstanding.
• · Accumulated distributed earnings (losses) decreased from $(5.5M) to $(12.0M).

12-08-2026

Stabilis Solutions reported a net loss of $4.6M for Q2 2026, widening sharply from a $0.6M loss in Q2 2025, as revenues fell 31% YoY to $11.9M. The decline was driven by lower LNG product revenue and the absence of service revenue, while the company also recorded a $2.9M time charter expense. However, operating cash flow improved significantly to $19.5M in H1 2026 from $5.5M a year ago, boosted by a $20.0M increase in deferred revenue.

• · Total assets increased to $99.4M at June 30, 2026 from $83.1M at December 31, 2025.
• · Total liabilities more than doubled to $40.9M from $16.4M, driven by a $19.3M noncurrent deferred revenue balance.
• · Stockholders' equity decreased to $58.4M from $66.7M due to the accumulated deficit widening to $45.7M.
• · Capital expenditures (acquisitions of fixed assets) totaled $7.6M in H1 2026, up from $1.1M in H1 2025.
• · Mexico revenue was essentially flat, increasing only 2.1% YoY in Q2 2026.
• · The company recorded a $2.9M time charter expense in Q2 2026, with no comparable expense in Q2 2025.
• · A non-cash time charter cancellation of $0.6M was recorded in H1 2026.
• · An impairment charge of $71,000 was recorded in H1 2026.
• · Net equity income from foreign joint ventures increased to $215,000 in Q2 2026 from $50,000 in Q2 2025.

12-08-2026

VEEA INC. reported a net loss of $4.0M for Q2 2026 versus a $7.4M loss in Q2 2025, while net sales surged to $176,221 from $72,927. However, operating expenses also rose sharply, with general and administrative costs increasing 42% to $6.8M, and the company posted a net loss of $8.7M for the first half of 2026 compared to a $3.1M loss in the prior-year period. Total assets grew to $30.1M and the company achieved positive stockholders' equity of $8.1M versus a deficit of $9.8M at year-end 2025, but cash used in operations worsened to $11.1M from $7.1M.

• · Inventories remained nearly flat at $9.56M (June 30, 2026) vs $9.65M (Dec 31, 2025).
• · Goodwill was $5.09M (June 30, 2026) vs $5.10M (Dec 31, 2025).
• · Intangible assets, net decreased slightly to $7.14M from $7.43M.
• · Revolving line of credit was fully repaid — $0 outstanding at June 30, 2026 vs $14.0M at Dec 31, 2025.
• · Related party liabilities fell sharply to $133,200 from $4.22M due to settlement for preferred stock.
• · Related party note payable was $0 at June 30, 2026 vs $2.34M at Dec 31, 2025.
• · Warrant liability decreased to $1.23M from $3.61M, and earn-out share liability fell to $643,200 from $2.54M.
• · The company had $1.06M in restricted cash at June 30, 2026, none at Dec 31, 2025.
• · Investments increased to $253,984 from $0 at year-end 2025.
• · Net cash used in financing activities was $13.3M (inflow) vs $5.8M in H1 2025.
• · Net sales for Q2 2026 were $176,221, up from $72,927 in Q2 2025, but remained a minimal revenue base.
• · Gross profit margin improved to approximately 78% in Q2 2026 from 94% in Q2 2025? (137,383/176,221=78%) vs (68,340/72,927=94%) — decline in gross margin.
• · Transaction costs of $73,024 were incurred in the current period, none in prior-year same period.
• · Total operating expenses for H1 2026 were $12.47M vs $10.75M in H1 2025, an increase of 16%.
• · Basic and diluted net loss per share for Q2 2026 was $(0.08) compared to $(0.19) in Q2 2025.
• · Weighted average shares outstanding for basic EPS was 51.99M (Q2 2026) vs 38.81M (Q2 2025).

12-08-2026

Cardinal Infrastructure Group Inc. reported strong revenue growth for Q2 and H1 2026, driven by acquisitions and organic expansion. Revenue for Q2 2026 was $226.9M, up 113.9% YoY, and H1 2026 revenue was $394.4M, up 109.9% YoY. However, net income attributable to the company declined 34.8% in Q2 to $4.7M and 36.0% in H1 to $8.1M, as higher costs and a $1.9M other expense weighed on profitability. The company completed a secondary public offering raising $319.0M and executed the ALGC acquisition, significantly expanding its balance sheet.

• · Q2 2026 basic EPS was $0.30 (no prior period provided); diluted EPS was $0.26.
• · H1 2026 basic and diluted EPS were both $0.53 (no prior period provided).
• · Total assets surged to $1.01B from $394.6M at year-end 2025, driven by the ALGC acquisition and equity offering.
• · Goodwill increased to $133.2M from $23.5M, and intangible assets rose to $101.9M from $15.5M.
• · Total debt (notes payable, current and non-current) increased to $197.0M from $119.3M.
• · Operating cash flow improved to $22.0M in H1 2026 from $16.3M in H1 2025.
• · Capital expenditures (purchases of property and equipment) were $34.0M in H1 2026 vs. $22.6M in H1 2025.
• · The company recorded a $1.9M other expense in Q2 2026 (primarily from the ALGC acquisition), compared to negligible amounts in prior periods.
• · Income tax benefit of $1.0M in Q2 2026 vs. a provision of $0.7M in Q2 2025.
• · Noncontrolling interests absorbed $6.5M of Q2 2026 net income (58.1%) vs. $2.3M (24.1%) in Q2 2025, reflecting the ALGC acquisition structure.

12-08-2026

CAVA Group reported strong Q2 FY26 results with revenue of $368.4M for the 12 weeks ended July 12, 2026, up 31.3% YoY from $280.6M, driven by restaurant revenue growth. Net income rose to $23.0M from $18.4M, a 25.3% increase. However, other comprehensive income turned to a loss of ($0.2M) vs a gain of $0.1M in the prior year period, and the company's accumulated deficit narrowed but remained significant at ($207.0M).

• · Restaurant revenue for 12 weeks ended July 12, 2026 was $365.4M vs $278.2M in prior year period.
• · CPG revenue and other for 12 weeks ended July 12, 2026 was $3.0M vs $2.4M in prior year period.
• · Total operating expenses for 12 weeks ended July 12, 2026 were $341.6M vs $261.0M in prior year period.
• · Income from operations for 12 weeks ended July 12, 2026 was $26.8M vs $19.6M in prior year period.
• · Basic EPS for 12 weeks ended July 12, 2026 was $0.20 vs $0.16 in prior year period; diluted EPS was $0.19 vs $0.16.
• · Goodwill remained unchanged at $1.9M.
• · The company had no debt outstanding as of July 12, 2026 (no debt line items on balance sheet).
• · Net cash used in investing activities for 28 weeks ended July 12, 2026 was $97.5M vs $177.4M in prior year period, primarily due to lower debt security purchases.
• · Debt refinancing costs of $0.8M were incurred in the current period vs $0 in prior year.

12-08-2026

Senior Credit Investments, LLC reported strong growth in net investment income for Q2 2026, with net investment income rising 60.8% YoY to $7.6M for the quarter and 54.0% YoY to $14.1M for the six-month period. However, the company experienced net unrealized depreciation of $1.9M in Q2 2026 and $2.9M for the six-month period, partially offsetting gains. Total assets grew to $621.7M as of June 30, 2026, up from $571.6M at year-end 2025, while net asset value per unit declined slightly to $1,769.49 from $1,787.98.

• · Net realized gain on investments was $0.1M for Q2 2026 and $0.2M for H1 2026.
• · Net change in unrealized depreciation on investments was $1.9M for Q2 2026 and $2.9M for H1 2026.
• · Distributions declared were $7.4M for Q2 2026 and $14.0M for H1 2026.
• · The company issued $30.0M in common units during H1 2026.
• · Cash used in operating activities was $42.0M for H1 2026, compared to $94.6M for H1 2025.
• · Cash provided by financing activities was $38.0M for H1 2026, compared to $98.5M for H1 2025.

12-08-2026

Oaktree Gardens OLP, LLC reported net investment income of $11,847 for Q3 FY2026, roughly flat versus $11,794 in Q3 FY2025, while total investment income rose 3.9% to $22,566. However, the company recorded net unrealized depreciation of $1,653 and realized gains of $44, leading to a net increase in net assets of $10,238, up 10.7% year-over-year. Net asset value per unit declined from $20.44 to $19.95, and the company continued to pay distributions, though cash flow from operations turned negative at -$6,269 for the nine months.

• · Net unrealized depreciation on investments was $1,659 for Q3 FY26, compared to $2,057 in Q3 FY25.
• · Net realized gains on investments were -$271 for Q3 FY26, versus +$2 in Q3 FY25.
• · Interest expense increased to $8,063 in Q3 FY26 from $7,639 in Q3 FY25.
• · Credit facility payable rose to $562,000 as of June 30, 2026 from $528,500 at September 30, 2025.
• · Cash and cash equivalents and restricted cash decreased to $32,321 as of June 30, 2026 from $40,322 at September 30, 2025.
• · Net cash used in operating activities for nine months ended June 30, 2026 was $6,269, compared to $281,810 used in the prior year period.
• · Distributions to unitholders increased to $42,200 for nine months ended June 30, 2026 from $33,500 in the prior year period.
• · The company issued 2,103 common units in Q3 FY26, raising $2,103 in proceeds.
• · Total portfolio investments, cash and cash equivalents and restricted cash represented 221.3% of net assets as of June 30, 2026, up from 210.7% at September 30, 2025.

12-08-2026

Black Rock Coffee Bar, Inc. reported a strong turnaround for the six months ended June 30, 2026, with net income of $5.0M compared to a net loss of $1.9M in the prior-year period, driven by 24.4% revenue growth to $118.5M. However, cash and cash equivalents declined sharply by 43.8% to $16.0M from $28.4M at year-end 2025, and the company's tax receivable agreement liability nearly doubled to $62.0M, signaling significant cash outflows and future obligations.

• · Interest expense, net decreased significantly from $6.2M to $0.9M for the six-month period, primarily due to debt restructuring.
• · The company's deferred income tax asset grew 37.8% to $72.7M from $52.8M at year-end 2025.
• · Total assets increased 16.6% to $392.4M from $336.4M at December 31, 2025.
• · Total liabilities increased 22.1% to $282.8M from $231.7M at year-end 2025.
• · Shareholders' equity attributable to Black Rock Coffee Bar, Inc. increased to $54.6M from $45.7M, driven by retained earnings turning positive at $1.5M vs. a deficit of $(60,000).
• · Noncontrolling interest decreased to $54.9M from $59.0M, reflecting the redemption of LLC Units.

12-08-2026

Unicycive Therapeutics reported a net loss of $1.7M for Q2 2026, a significant improvement from a $6.4M loss in Q2 2025, driven largely by a $8.0M non-cash gain from the change in fair value of warrant liability. However, operating losses widened to $10.1M from $7.0M year-over-year, and the six-month net loss increased to $14.5M from $5.9M, reflecting higher R&D and G&A spending. The company strengthened its balance sheet with $44.2M in cash and equivalents as of June 30, 2026, up from $29.2M at year-end 2025, following a $34.0M net cash raise from a secondary public offering.

• · Total assets increased to $72.0M as of June 30, 2026 from $49.1M at December 31, 2025.
• · Total liabilities remained nearly flat at $18.8M (June 30, 2026) vs $18.9M (Dec 31, 2025).
• · Stockholders' equity grew to $53.3M from $30.2M, driven by equity issuances.
• · Accumulated other comprehensive loss worsened to $(23,000) from $(1,000).
• · Series A-2 Prime preferred stock was fully converted into common stock during H1 2026.
• · Stock-based compensation expense increased to $3.6M in H1 2026 from $1.1M in H1 2025.
• · The company had no debt or interest expense in H1 2026, compared to $13,000 interest expense in H1 2025.

12-08-2026

Liquidia Corporation reported a dramatic turnaround in Q2 2026, with total revenue surging to $171.7M from $8.8M in Q2 2025, driven by product sales of $170.4M (vs. $6.5M prior year). The company achieved net income of $74.7M for the quarter, compared to a net loss of $41.6M in the prior year period. However, operating expenses also increased significantly, with R&D expenses up 185% and SG&A up 48% year-over-year, reflecting continued investment in commercialization and pipeline development.

• · R&D expenses increased 185% YoY to $17.2M in Q2 2026, reflecting continued investment in pipeline development.
• · SG&A expenses increased 48% YoY to $57.4M in Q2 2026, driven by commercialization efforts.
• · The company generated $133.2M in operating cash flow in H1 2026, a significant improvement from $70.2M used in H1 2025.
• · Customer concentration remains high: Customer A and Customer B together accounted for 91% of gross product sales in H1 2026.
• · The company had $287.7M in cash, cash equivalents, and restricted cash as of June 30, 2026, up from $194.2M at the start of the year.
• · Total liabilities increased to $326.8M as of June 30, 2026, from $283.2M at December 31, 2025.
• · The company recorded an income tax expense of $6.975M in Q2 2026, compared to none in the prior year period.

12-08-2026

Bluejay Diagnostics, Inc. reported a net loss of $2.3M for Q2 2026 (vs. $2.0M loss in Q2 2025) and $4.2M for H1 2026 (vs. $3.8M loss in H1 2025), driven by a 62% increase in R&D expenses. However, the company strengthened its balance sheet by raising $7.6M net in a June 2026 private placement, boosting cash to $9.6M from $5.2M at year-end 2025. The company remains pre-revenue with no product sales, and its accumulated deficit grew to $45.8M.

• · No revenue generated; company is pre-revenue.
• · Net loss per share improved to $1.12 in Q2 2026 from $5.64 in Q2 2025 due to a 500% increase in weighted average shares outstanding (2,079,263 vs 346,780).
• · Operating cash flow improved slightly to -$3.1M in H1 2026 from -$3.2M in H1 2025.
• · Financing activities provided $7.7M in H1 2026, primarily from the June 2026 private placement of pre-funded warrants.
• · Property and equipment increased to $1.6M from $1.5M, with $1.4M in construction-in-process.
• · Total liabilities nearly doubled to $2.1M from $1.1M at year-end 2025, driven by higher accounts payable and accrued expenses.
• · Outstanding warrants include 2.7M pre-funded warrants (exercise price $0.0001) and 3.7M each of Series G and H warrants (exercise price $2.075).

12-08-2026

Lexeo Therapeutics reported a net loss of $25.9M for Q2 2026, narrowing from $26.1M in Q2 2025, while the six-month net loss improved to $46.1M from $58.8M. Revenue remained absent as the company continues to invest in R&D, which increased 29% to $19.0M in Q2. However, general and administrative expenses dropped sharply to $9.0M from $16.0M, driving the overall operating loss reduction. Cash and equivalents rose to $92.8M from $63.0M at year-end 2025, bolstered by $25.0M in ATM proceeds, but total assets declined slightly to $254.9M.

• · Net cash used in operating activities improved to $38.7M for H1 2026 from $48.9M in H1 2025.
• · Investing activities provided $41.7M in H1 2026 vs. using $23.6M in H1 2025, driven by $53.7M in proceeds from sales/maturities of investments.
• · Financing activities provided $26.9M in H1 2026, primarily from $25.0M gross ATM proceeds and $2.4M from warrant exercises.
• · Stock-based compensation expense rose to $8.4M in H1 2026 from $6.8M in H1 2025.
• · Total stockholders' equity decreased to $235.1M from $246.7M at year-end 2025.
• · Unrealized loss on U.S. Treasury securities was $0.5M in H1 2026 vs. a gain of $0.1M in H1 2025.
• · Weighted-average shares outstanding increased to 85.6M in Q2 2026 from 43.6M in Q2 2025, reflecting equity issuances.

12-08-2026

Enanta Pharmaceuticals reported a net loss of $19.5M for Q3 FY2026 (three months ended June 30, 2026), widening from an $18.3M loss in the prior-year quarter, as royalty revenue declined 21.6% YoY to $14.4M. For the nine-month period, the net loss narrowed 29.5% to $44.5M from $63.2M, driven by a 22.8% reduction in total operating expenses. The company strengthened its balance sheet with a $69.9M public offering in October 2025, boosting stockholders' equity to $101.1M from $64.7M at fiscal year-end, though cash used in operations increased to $28.8M from $12.8M.

• · Interest expense increased to $4.1M in Q3 FY2026 from $1.6M in Q3 FY2025, a 155% rise.
• · Cash used in operating activities for the nine months ended June 30, 2026 was $28.8M, more than double the $12.8M in the prior-year period.
• · Total liabilities decreased to $195.8M at June 30, 2026 from $216.0M at September 30, 2025, driven by a reduction in the long-term portion of the royalty sale liability.
• · The company held $178.1M in U.S. Treasury notes as marketable securities at June 30, 2026, up from $156.6M at September 30, 2025.
• · Accumulated deficit widened to $449.5M at June 30, 2026 from $404.9M at September 30, 2025.

12-08-2026

WhiteFiber, Inc. reported total revenues of $28.8M for Q2 2026 (up 54.5% YoY from $18.7M) and $50.8M for H1 2026 (up 43.3% YoY from $35.4M), driven by strong growth in cloud services (+43.4% QoQ, +29.1% YoY for H1) and colocation services (+173.4% QoQ, +182.2% YoY for H1). However, the company's net loss widened significantly to $15.0M in Q2 2026 (vs. $8.8M in Q2 2025) and $27.0M in H1 2026 (vs. $7.4M in H1 2025), as operating expenses surged 37.0% QoQ and 67.0% YoY for H1, including a $5.0M impairment of capitalized software assets. Total assets grew 35.2% to $880.9M from $651.4M at year-end 2025, while total liabilities more than tripled to $543.5M (from $168.9M) due to new debt and convertible note issuance, and shareholders' equity declined 30.1% to $337.4M (from $482.5M). Cash and cash equivalents fell 51.0% to $56.1M from $114.4M at year-end 2025, despite $89.1M in operating cash flow, as heavy capital expenditures of $344.7M outpaced financing inflows.

• · The company issued $222.1M in convertible debt and $53.3M in third-party debt during H1 2026, while also purchasing a $120.0M zero-strike call option.
• · Capital expenditures on property, plant, and equipment totaled $344.7M in H1 2026, up from $131.0M in H1 2025.
• · Operating cash flow turned positive to $89.1M in H1 2026 from negative $6.8M in H1 2025, driven largely by a $63.6M increase in deferred revenue.
• · Accumulated deficit more than doubled to $51.6M from $24.5M at year-end 2025.
• · The company established several new subsidiaries in 2025-2026, including entities in Canada, Japan, Australia, Singapore, and the British Virgin Islands.
• · Weighted average diluted shares outstanding increased 43.0% to 38.7M in Q2 2026 from 27.0M in Q2 2025.
• · Loss per share (basic and diluted) worsened to $(0.39) in Q2 2026 from $(0.33) in Q2 2025, and to $(0.70) in H1 2026 from $(0.27) in H1 2025.

12-08-2026

Milestone Pharmaceuticals reported its first-ever product revenue of $0.6M for Q2 2026 and $0.8M for H1 2026 from CARDAMYST, compared to zero revenue in the prior-year periods. However, the net loss widened significantly to $28.6M in Q2 2026 (vs. $13.0M in Q2 2025) and $54.7M in H1 2026 (vs. $33.7M in H1 2025), driven by a surge in SG&A expenses to $22.6M (from $8.9M) as the company scaled commercial operations. Cash and cash equivalents rose sharply to $169.7M at June 30, 2026 from $73.0M at year-end 2025, bolstered by $75.0M in proceeds from a royalty financing arrangement and $17.4M from warrant exercises.

• · Inventory increased to $4.7M at June 30, 2026 from $0.6M at December 31, 2025, with work-in-process of $4.3M and finished goods of $0.4M.
• · Accounts receivable, net was $2.7M at June 30, 2026 (vs. zero at year-end 2025), reflecting initial product sales.
• · Deferred revenue of $1.0M was recorded at June 30, 2026 (vs. zero at year-end 2025).
• · Interest expense rose to $4.7M in Q2 2026 (from $1.0M in Q2 2025) and $8.9M in H1 2026 (from $1.9M in H1 2025), driven by the new royalty financing obligation and convertible notes.
• · Non-cash interest expense related to royalty financing obligation was $6.8M in H1 2026.
• · Net cash used in operating activities increased to $38.8M in H1 2026 from $26.5M in H1 2025.
• · The company issued 5.5M common shares for net proceeds of $10.9M in H1 2026.
• · Series A common stock warrant exercises contributed $17.4M in net proceeds in H1 2026.
• · Total liabilities more than doubled to $163.4M at June 30, 2026 from $71.8M at December 31, 2025, primarily due to the $81.8M royalty financing obligation.

12-08-2026

HG Holdings, Inc. (STLY) reported total revenues of $8.27M for the six months ended June 30, 2026, up 22% from $6.78M in the prior-year period, driven by strong growth in management fees and net premium written. Net income attributable to shareholders surged to $1.40M from $0.63M, a 122% increase. However, basic EPS for Q2 2026 fell sharply to $0.17 from $0.35 in Q2 2025 due to a significantly higher share count following a large equity issuance in mid-2025.

• · Net cash provided by operating activities for H1 2026 was $4.95M, up 70% from $2.91M in H1 2025.
• · The company repurchased 60,000 shares of common stock in Q1 2026 for $287,000.
• · Investments in related parties remained stable at $18.86M as of June 30, 2026.
• · Escrow liabilities increased to $9.65M from $6.59M at year-end 2025.
• · The company had a net loss of $180,000 in Q1 2026 from its segment reported separately (likely ACMAT Corporation).

12-08-2026

Cypherpunk Technologies reported a net loss of $37.8M for H1 2026, wider than the $32.1M loss in H1 2025, while revenue remained absent (zero). However, Q2 2026 swung to a net income of $39.4M from a $16.6M loss in Q2 2025, driven by a $46.0M gain from the change in fair value of an embedded derivative. Operating cash burn improved to $6.1M from $29.0M year-over-year, but cash reserves plummeted 46% to $7.6M from $14.0M at year-end 2025.

• · Q2 2026 reported a net income of $39.4M, a $56.0M swing from the $16.6M loss in Q2 2025, largely due to a $46.0M non-cash gain from change in fair value of embedded derivative.
• · H1 2026 net loss widened to $37.8M from $32.1M in H1 2025, despite a 72% reduction in operating expenses to $9.5M.
• · Cash burn from operations improved dramatically to $6.1M in H1 2026 from $29.0M in H1 2025.
• · Cash position fell 46% to $7.6M at Jun 30, 2026 from $14.0M at Dec 31, 2025, partly due to $13.5M in digital asset purchases and a $5.0M other investment.
• · Digital assets receivable decreased 12% to $129.4M from $147.4M over the same period.
• · The company raised $19.2M (net) through ATM stock sales in H1 2026, issuing 22.2 million shares.
• · Stock-based compensation was $4.3M in H1 2026 vs $2.7M in H1 2025.
• · Accumulated deficit grew to $500.3M at Jun 30, 2026 from $462.5M at Dec 31, 2025.

12-08-2026

Protalix BioTherapeutics reported a strong turnaround for the six months ended June 30, 2026, with net income of $22.1M compared to a net loss of $3.5M in the prior year period, driven by a surge in license and R&D services revenue to $26.4M (from $0.3M). Total revenue more than doubled to $53.6M, and operating income swung to $25.8M from a loss of $3.0M. However, revenues from selling goods grew only modestly (7.1% YoY to $27.2M), and the company's cash position improved significantly to $27.4M from $14.7M at year-end 2025.

• · Basic EPS for six months ended June 30, 2026 was $0.28, compared to ($0.04) in the prior year period.
• · Diluted EPS for six months ended June 30, 2026 was $0.27, compared to ($0.04) in the prior year period.
• · Cost of revenues decreased to $11.9M for the six months ended June 30, 2026 from $14.1M in the prior year period, a decline of 15.4%.
• · Research and development expenses increased slightly to $9.8M from $9.5M (3.3% increase).
• · Selling, general, and administrative expenses increased to $6.2M from $5.2M (17.9% increase).
• · Accounts receivable increased to $16.5M from $8.8M at year-end 2025, an increase of 86.7%.
• · The company had no proceeds from issuance of common stock under the Sales Agreement in the six months ended June 30, 2026, compared to $6.8M in the prior year period.
• · Taxes on income were $3.9M for the six months ended June 30, 2026, compared to $0.4M in the prior year period.
• · Finished goods inventory increased to $18.0M from $10.4M at year-end 2025, a 73.1% increase.
• · The company had a net increase in cash and cash equivalents of $12.7M for the six months ended June 30, 2026, compared to a net decrease of $1.9M in the prior year period.

12-08-2026

Capstone Holding Corp. reported a net loss of $1.38M for Q2 2026, widening from a $0.70M loss in Q2 2025, while net sales surged 67% to $21.48M from $12.85M. For the six-month period, net loss grew to $3.30M from $2.43M, despite net sales rising 64% to $34.12M. The company's cash position fell sharply to $0.23M from $0.73M at year-end 2025, and total debt increased to $25.46M from $23.36M.

• · Gross profit for Q2 2026 was $6.00M, up from $3.13M in Q2 2025.
• · Selling, general and administrative expenses for Q2 2026 were $5.51M, up from $3.39M in Q2 2025.
• · Interest expense for Q2 2026 was $1.96M, up from $0.44M in Q2 2025.
• · Net cash used in operating activities for H1 2026 was $3.18M, compared to $3.99M in H1 2025.
• · Net cash provided by financing activities for H1 2026 was $2.81M, down from $4.76M in H1 2025.
• · The company acquired CSI for an aggregate purchase consideration of $4.20M, including $2.63M cash, a $1.25M seller note, and a $0.25M earn-out.
• · Goodwill increased by $0.76M to $18.48M as of June 30, 2026, primarily from the CSI acquisition.
• · Derivative liability decreased sharply from $0.70M at year-end 2025 to $7,000 at June 30, 2026.
• · Line of credit borrowings increased to $12.61M from $10.31M at year-end 2025.
• · The company issued 2,557,198 shares of common stock pursuant to Senior Convertible Notes during Q2 2026.

12-08-2026

Sutro Biopharma reported a net loss of $38.5M for Q2 2026, a significant increase from $11.5M in Q2 2025, driven by a sharp decline in revenue to $9.8M from $63.7M. For the six months ended June 30, 2026, net loss improved to $77.0M from $87.5M, but revenue fell to $24.4M from $81.1M. The company strengthened its balance sheet with a public offering raising $102.7M, but continues to face substantial operating losses and a growing deferred royalty obligation.

• · Total operating expenses decreased to $39.7M in Q2 2026 from $67.1M in Q2 2025, and to $83.9M in H1 2026 from $153.0M in H1 2025.
• · Research and development expenses declined to $31.7M in Q2 2026 from $38.3M in Q2 2025, and to $68.2M in H1 2026 from $89.9M in H1 2025.
• · Restructuring and related costs were minimal in 2026 ($0.2M in Q2, $0.2M in H1) compared to $18.4M in Q2 2025 and $39.5M in H1 2025.
• · Stockholders' deficit improved to $103.3M as of June 30, 2026 from $132.5M at December 31, 2025, primarily due to the public offering.
• · Net cash used in operating activities improved to $80.5M in H1 2026 from $112.6M in H1 2025.
• · The company issued 7,868,383 shares in a public offering during H1 2026, raising net proceeds of $102.7M.

12-08-2026

Arbutus Biopharma reported a net loss of $5.1M for Q2 2026, compared to net income of $2.5M in Q2 2025, driven by a sharp decline in collaboration and license revenue. However, for the first half of 2026, the company recorded net income of $164.6M, a dramatic swing from a net loss of $22.0M in H1 2025, primarily due to a $179.4M license revenue from Genevant recognized in Q1 2026. Total revenue for H1 2026 surged to $180.1M from $12.5M in the prior year, but Q2 revenue alone fell 91% year-over-year to $1.0M.

• · Q2 2026 collaborations and licenses revenue fell to $0.2M from $10.2M in Q2 2025.
• · Non-cash royalty revenue declined to $0.2M in Q2 2026 from $0.5M in Q2 2025.
• · General and administrative expenses increased to $3.9M in Q2 2026 from $3.3M in Q2 2025.
• · Interest income decreased to $0.8M in Q2 2026 from $1.0M in Q2 2025.
• · Net cash used in operating activities improved to $14.1M in H1 2026 from $29.1M in H1 2025.
• · Cash and cash equivalents decreased to $19.2M as of June 30, 2026 from $37.4M a year earlier.
• · Total stockholders' equity increased to $258.7M as of June 30, 2026 from $82.9M as of June 30, 2025.
• · Contingent consideration liability increased to $8.8M as of June 30, 2026 from $8.4M as of December 31, 2025.

12-08-2026

TScan Therapeutics reported a net loss of $30.4M for Q2 2026, improving from a $37.0M loss in Q2 2025, driven by a 25% reduction in R&D expenses. However, collaboration and license revenue fell sharply to $1.1M from $3.1M in the prior-year quarter, and cash and cash equivalents declined 34% to $100.2M as of June 30, 2026, from $152.4M at year-end 2025.

• · Cash burn from operations improved to $51.8M in H1 2026 from $70.9M in H1 2025, a 26.9% reduction.
• · The company had no marketable securities as of June 30, 2026, compared to $148.2M in cash equivalents at December 31, 2025.
• · Current portion of long-term debt increased to $11.7M at June 30, 2026 from $0 at December 31, 2025.
• · Total liabilities decreased slightly to $102.4M from $105.7M at year-end 2025.
• · Stock-based compensation expense fell to $4.8M in H1 2026 from $6.7M in H1 2025, a 27.9% decline.
• · Deferred revenue decreased to $0.6M from $2.6M at December 31, 2025, reflecting revenue recognition.
• · Accrued legal services and license fee increased to $0.7M from $0.3M at year-end 2025.

12-08-2026

LiqTech International reported a net loss of $3.0M for Q2 2026 (wider than $2.2M in Q2 2025) and a net loss of $5.7M for H1 2026 (wider than $4.5M in H1 2025). Revenue declined 12.0% YoY for Q2 to $4.4M and 11.2% YoY for H1 to $8.5M. However, cash and restricted cash more than tripled to $15.7M at June 30, 2026 from $5.1M at December 31, 2025, driven by a $18.1M capital raise and a $3.0M note repayment, and the company reduced total liabilities from $16.9M to $12.1M.

• · Revenue decline of 12.0% YoY in Q2 and 11.2% YoY in H1, while cost of goods sold fell only 10.6% and 13.7% respectively, leading to a 24.6% Q2 gross profit decline.
• · Operating expenses increased 4.0% in Q2 and 9.4% in H1, driven by higher selling, R&D and G&A costs.
• · Net cash used in operating activities deepened to $5.0M in H1 2026 from $2.9M in H1 2025, reflecting wider net loss and increased working capital outflows.
• · The company issued 20,000,000 common shares in a capital raise for $18.1M net proceeds; 3,000,000 common shares were issued to repay notes payable.
• · Total equity improved to $25.8M from $10.4M due to the capital raise; total liabilities fell to $12.1M from $16.9M.
• · Loss per share (basic and diluted) was $0.14 for Q2 2026 (same as Q2 2025) and $0.32 for H1 2026 vs $0.30 for H1 2025.

12-08-2026

Xilio Therapeutics reported a net loss of $6.4M for Q2 2026, a significant improvement from a $15.8M loss in Q2 2025, driven by a surge in collaboration and license revenue to $18.7M (up 131% YoY). However, operating expenses remained high at $22.2M, and the company's cash position slightly declined to $136.0M from $137.5M at year-end 2025, while operating cash flow was negative $41.1M for the first half of 2026.

• · Total operating expenses for Q2 2026 were $22.2M, nearly flat compared to $22.5M in Q2 2025.
• · Research and development expenses decreased 5% YoY to $14.6M in Q2 2026, while general and administrative expenses increased 7% YoY to $7.6M.
• · The company raised $37.3M in net proceeds from a follow-on offering of prefunded warrants in H1 2026.
• · Deferred revenue decreased significantly from $60.7M at Dec 31, 2025 to $35.3M at June 30, 2026, as revenue was recognized from Gilead and AbbVie collaborations.
• · Common stock warrant liabilities increased to $30.2M from $29.6M at year-end 2025.
• · The company's accumulated deficit grew to $434.7M as of June 30, 2026, up from $418.8M at Dec 31, 2025.

12-08-2026

12-08-2026

QHSLab reported revenue growth of 40.0% YoY to $847,490 for Q2 2026, and 26.0% YoY to $1,576,175 for the first half of 2026, driven mainly by a surge in Integrated Service Program and new Clinical Study Revenue. However, cash and cash equivalents declined sharply by 50.1% to $317,392 from $636,157 at year-end 2025, and the company reported an operating loss for the six-month period. Net income turned positive in Q2 2026 at $38,030 versus a loss of $52,958 in Q2 2025, yet the accumulated deficit widened to $3,969,427.

• · Integrated Service Program revenue surged 86.4% to $491,399 in Q2 2026 from $263,628 in Q2 2025.
• · Clinical Study Revenue was $29,700 in Q2 2026, compared to none in Q2 2025.
• · Allergy Diagnostic Kit sales declined 0.8% in Q2 and 8.2% in H1 YoY.
• · Immunotherapy Treatment sales fell 21.6% in H1 YoY.
• · Interest expense dropped 88.8% to $7,215 in Q2 2026 from $64,484 in Q2 2025.
• · General and administrative expenses increased 70.5% YoY in Q2.
• · Cash used in operating activities was $208,061 in H1 2026 vs. cash provided of $77,484 in H1 2025.
• · Company had due to related party of $95,548 at June 30, 2026 vs. $0 at December 31, 2025.

12-08-2026

DeltaSoft Corp filed its Form 10-Q for the quarter ended June 30, 2026, reporting a net loss of ($9,561) compared to net income of $1,130 in the same quarter last year, a steep decline driven by a complete absence of revenue versus $10,109 in the prior-year quarter. Operating expenses nearly doubled to $9,736 from $4,979, while cash dropped sharply to $8,449 from $25,470 at March 31, 2026. The company has no revenue and relies on a related party loan of $26,231 to fund operations.

• · Professional fees jumped from $896 to $4,323, a 382.5% increase.
• · General and administrative expenses rose from $4,083 to $5,413, a 32.6% increase.
• · Amortization expense increased from $4,083 to $4,291.
• · Investing activities used $3,736 for software development costs (none in prior period).
• · No proceeds from related party loan in the current quarter versus $4,000 in prior quarter.
• · Accumulated deficit widened from ($986) at March 31, 2026 to ($10,547) at June 30, 2026.
• · Current ratio worsened: current assets of $28,449 vs current liabilities of $26,455 (1.08:1) compared to $45,470 vs $34,470 (1.32:1) at year end.
• · Accounts payable dropped from $8,239 to $224, indicating paydown of obligations.

12-08-2026

Dyadic International reported total revenue of $961,138 for Q2 2026, essentially flat compared to $966,630 in Q2 2025, while the net loss widened to $2,123,884 from $1,793,774. For the first half of 2026, total revenue increased 52.3% to $2,072,094, driven by higher grant and R&D revenue, but the net loss also grew to $4,078,567 from $3,821,353. Operating expenses rose across the board, and cash used in operations increased significantly, with cash and restricted cash declining to $2,981,013 from $5,853,499 at year-end 2025.

• · Grant revenue increased 66.4% to $837,252 in Q2 2026 from $503,181 in Q2 2025, and 85.6% to $1,324,618 in H1 2026 from $713,653 in H1 2025.
• · License and milestone revenue was zero in Q2 2026 and $220,000 in H1 2026, compared to $250,000 in both Q2 2025 and H1 2025.
• · Costs of grant revenue rose to $860,843 in Q2 2026 from $465,134 in Q2 2025, and to $1,312,526 in H1 2026 from $636,312 in H1 2025.
• · Accounts receivable increased to $1,302,439 at June 30, 2026 from $1,090,297 at December 31, 2025.
• · Accrued expenses rose to $1,395,680 at June 30, 2026 from $967,974 at December 31, 2025.
• · Stock-based compensation expense decreased to $283,671 in H1 2026 from $565,492 in H1 2025.
• · The company had a working capital deficit of $2,387,244 at June 30, 2026, compared to a positive working capital of $1,232,410 at December 31, 2025.
• · No proceeds from exercise of stock options in H1 2026 vs $24,249 in H1 2025.

12-08-2026

Cardiff Lexington Corp (CDIX) reported a net loss of $2.48M for Q2 2026 (vs. $1.23M loss in Q2 2025) and a net loss of $5.57M for H1 2026 (vs. $1.68M loss in H1 2025), driven by a decline in revenue and a sharp increase in interest expense. Revenue fell 22.6% YoY in Q2 to $2.16M and 23.2% YoY in H1 to $4.38M, while operating income swung from a $0.61M profit to a $0.54M loss in Q2. However, the company improved its stockholders' equity from a deficit of $2.47M at year-end 2025 to a positive $1.76M at June 30, 2026, and reduced net cash used in operations from $1.89M to $0.67M.

• · Gross profit margin declined: Q2 2026 gross profit was $1.18M (54.7% of revenue) vs. $1.70M (60.8% of revenue) in Q2 2025.
• · Selling, general and administrative expenses increased 37.7% YoY in Q2 2026 to $1.36M.
• · Share-based compensation surged to $1.03M in H1 2026 from $97,500 in H1 2025.
• · Derivative liability of $1.09M was recognized at June 30, 2026, with a loss of $0.44M on issuance and fair value changes in H1 2026.
• · Line of credit balance increased to $21.14M at June 30, 2026 from $17.21M at December 31, 2025.
• · Convertible notes payable (current portion) net of discounts rose to $0.30M from $0.12M at year-end 2025.
• · Accrued expenses – related parties dropped sharply from $4.65M to $0.23M, largely due to conversion of salaries into equity and notes.
• · Net cash used in operations improved to $0.67M in H1 2026 from $1.89M in H1 2025.
• · Cash provided by financing activities was $0.57M in H1 2026 vs. $1.26M in H1 2025.
• · Basic and diluted loss per share improved to $(0.18) in Q2 2026 from $(0.24) in Q2 2025, despite larger net loss, due to a higher share count (15.3M vs. 6.2M weighted average).

12-08-2026

Aprea Therapeutics reported a net loss of $3.6M for Q2 2026, widening from a $3.2M loss in Q2 2025, driven by a 29% increase in R&D spending and the elimination of grant revenue. However, the company significantly strengthened its balance sheet, ending the quarter with $41.2M in cash versus $14.6M at year-end 2025, following a $32.7M net financing from stock and warrant issuances. The net loss per share improved dramatically to ($0.07) from ($0.53) due to a large increase in weighted-average shares outstanding.

• · Net cash used in operating activities improved to $6.0M in H1 2026 from $6.8M in H1 2025.
• · Interest income increased to $493,707 in H1 2026 from $382,753 in H1 2025, reflecting higher cash balances.
• · Foreign currency gain of $10,664 in H1 2026 versus a loss of $80,927 in H1 2025.
• · Stock-based compensation decreased to $204,261 in H1 2026 from $255,363 in H1 2025.
• · No conversion of preferred stock occurred in H1 2026, compared to $583,702 in H1 2025.
• · The company had no grant revenue in 2026, compared to $280,574 in H1 2025.

12-08-2026

12-08-2026

Neonode Inc. reported a net loss of $2.1M for Q2 2026 (vs. $1.9M loss in Q2 2025) and a net loss of $4.0M for H1 2026 (vs. $3.6M loss in H1 2025), with total revenues declining 20% YoY in Q2 to $477K and 2% YoY in H1 to $1.1M. While license fees grew 9% YoY in Q2 and 15% in H1, non-recurring engineering revenue dropped sharply by 82% in Q2 and 73% in H1, and operating expenses rose 3% in Q2 and 6% in H1, widening operating losses. Cash and cash equivalents fell 16% from year-end 2025 to $21.3M as of June 30, 2026.

• · Gross margin declined 21% YoY in Q2 2026 to $468K (from $593K) and 2% in H1 2026 to $1.1M (from $1.1M).
• · Research and development expenses decreased 7% YoY in Q2 2026 to $1.0M and 7% in H1 2026 to $1.9M.
• · Sales and marketing expenses increased 24% YoY in Q2 2026 to $739K and 9% in H1 2026 to $1.3M.
• · General and administrative expenses increased 1% YoY in Q2 2026 to $1.0M and 17% in H1 2026 to $2.2M.
• · Operating loss widened 10% YoY in Q2 2026 to $2.3M and 8% in H1 2026 to $4.4M.
• · Other income, net increased 45% YoY in Q2 2026 to $183K and 39% in H1 2026 to $392K.
• · Income from discontinued operations fell 76% YoY in Q2 2026 to $28K and 85% in H1 2026 to $28K.
• · Basic and diluted net loss per share was $0.13 in Q2 2026 vs. $0.11 in Q2 2025, and $0.24 in H1 2026 vs. $0.21 in H1 2025.
• · Net cash used in operating activities increased 29% YoY in H1 2026 to $4.0M (from $3.1M).
• · The company had no debt beyond lease obligations, with total liabilities of $2.9M as of June 30, 2026.
• · Accumulated deficit grew to $219.6M as of June 30, 2026 from $215.6M at year-end 2025.

12-08-2026

Nucor reported strong Q2 2026 results with net sales of $10,397M, up 23% YoY, and net earnings attributable to stockholders of $1,156M, up 92% YoY. For the first half, net sales rose 22% to $19,893M and net earnings more than doubled to $1,899M. However, cash flow from operations improved significantly, but the company continued to repurchase shares and pay dividends, while capital expenditures declined.

• · Diluted EPS for Q2 2026 was $5.04, up from $2.60 in Q2 2025; H1 2026 diluted EPS was $8.27, up from $3.26 in H1 2025.
• · Total assets increased to $36,954M as of July 4, 2026, from $35,104M at December 31, 2025.
• · Total debt (short-term and long-term) decreased to $7,099M as of July 4, 2026, from $7,121M at December 31, 2025.
• · The company repurchased $475M of treasury stock in H1 2026, compared to $500M in H1 2025.
• · Cash dividends paid remained flat at $258M in both H1 2026 and H1 2025.
• · Capital expenditures declined 32% YoY to $1,232M in H1 2026.
• · Cash and cash equivalents increased to $2,478M as of July 4, 2026, from $2,260M at December 31, 2025.
• · The company reported a net unrealized loss on hedging derivatives of $25M (net of tax) for H1 2026, compared to a loss of $6M in H1 2025.
• · Foreign currency translation loss was $31M (net of tax) for H1 2026, compared to a gain of $40M in H1 2025.